CSIMarket
 


Zynerba Pharmaceuticals Inc   (ZYNE)
Other Ticker:  
 

Cumulative Zynerba Pharmaceuticals Inc 's Working Capital Ratio for Trailing Twelve Months Period

ZYNE's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ZYNE Working Capital Ratio for Trailing Twelve Months Period

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities Growth 17.95 % 7.76 % -7.39 % -13.46 % -4.99 %
Y / Y Current Assets Growth -40.16 % -35.03 % -31.72 % -30.95 % -31.91 %
Working Capital Ratio for Trailing Twelve Months Period 5.13 6.06 6.87 7.41 7.83
Total Ranking # 732 # 676 # 688 # 658 # 750
Seq. Current Liabilities Growth 16.94 % 4.77 % -2.74 % -1.01 % 6.83 %
Seq. Current Assets Growth -17.41 % -13.14 % -9.91 % -7.42 % -10.32 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Jun 30 2023
On the trailing twelve months basis Due to increase in Current Liabilities in the II. Quarter to $11 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 5.13 below Zynerba Pharmaceuticals Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 325 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Zynerba Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about ZYNE
Working Capital Ratio ZYNE in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 326
Sector # 594
S&P 500 # 1094


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
9.81 7.61 5.1
(Dec 31 2017)   (Jun 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Adicet Bio Inc   14.08 
Tyme Technologies Inc.  14.06 
Olema Pharmaceuticals inc   14.03 
Kalvista Pharmaceuticals Inc   14.00 
Rapt Therapeutics Inc   13.94 
Iveric Bio Inc   13.91 
Immutep Limited  13.90 
Prelude Therapeutics Inc  13.66 
Landos Biopharma Inc   13.58 
Lianbio  13.54 
Atai Life Sciences N v   13.53 
Xenetic Biosciences Inc   13.42 
Pyxis Oncology Inc   13.40 
Eledon Pharmaceuticals Inc   13.19 
Lumos Pharma Inc   13.05 
Histogen Inc   12.91 
Centessa Pharmaceuticals Plc  12.79 
Cerevel Therapeutics Holdings Inc   12.77 
Dianthus Therapeutics Inc   12.76 
Coya Therapeutics Inc   12.75 
Crinetics Pharmaceuticals Inc   12.65 
Larimar Therapeutics Inc   12.45 
Pds Biotechnology Corp  12.42 
Vanda Pharmaceuticals Inc   12.37 
Cytokinetics Incorporated  12.30 
Compass Pathways Plc  12.15 
Cogent Biosciences Inc   12.11 
89bio Inc   11.98 
Alx Oncology Holdings Inc  11.95 
Inozyme Pharma Inc   11.94 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com